Massachusetts is currently home to 3149 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
The Role of Electrophysiology Testing in Survivors of Unexplained Cardiac Arrest
Recruiting
Sudden cardiac death (SCD) remains a major cause of mortality within developed nations despite aggressive efforts to reduce its societal burden. Despite extensive clinical and genetic investigations, a subgroup of cardiac arrests remain unexplained, highlighting the potential contribution of additional cardiac conditions that may not be identified with contemporary diagnostic algorithms. The EPS ARREST study aims to evaluate the role of invasive electrophysiology study within this patient popula... Read More
Gender:
ALL
Ages:
All
Trial Updated:
12/02/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Sudden Cardiac Death
Nutrition in Patient With Critical Limb Ischemia
Recruiting
A prospective pilot study examining nutritional supplements among vascular surgery patients with Critical Limb Ischemia (CLI). CLI patients have a high rate of malnutrition and has the potential to benefit greatly from nutritional intervention. The investigators plan to evaluate nutrition and functional status of patients by assessing objective lab values and the use of the hand grip strength test. Providing perioperative nutritional supplements to patients has potentially improved their nutriti... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
12/01/2024
Locations: Boston Medical Center, Boston, Massachusetts
Conditions: Critical Limb Ischemia, Malnutrition, Nutritional Supplements
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Recruiting
This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Pembrolizumab in patients with advanced solid tumors who have exhausted all standard therapy available or are intolerant of the same.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/29/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Non Small Cell Lung Cancer, Esophageal Cancer, Head and Neck Squamous Cell Carcinoma, Pancreas Adenocarcinoma, Biliary Tract Cancer, Prostate Cancer, Urothelial Carcinoma, Colorectal Cancer, Triple Negative Breast Cancer, High Grade Ovarian Serous Adenocarcinoma, Diffuse Large B Cell Lymphoma
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
Recruiting
This study is referred to as the "umbrella master protocol" for pembrolizumab (MK-3475) in the treatment of non-small cell lung cancer (NSCLC). This pembrolizumab NSCLC umbrella master protocol uses a platform design and consists of this master screening study and seven substudies. Each substudy will enroll a different population of NSCLC participants. The goal of this umbrella master protocol is to screen potential participants with NSCLC for enrollment into 1 of 7 substudies. Participants mus... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/28/2024
Locations: Massachusetts General Hospital ( Site 0003), Boston, Massachusetts
Conditions: Carcinoma, Non-Small-Cell Lung
Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Tablet-01)
Recruiting
People with brainstem stroke, advanced amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease), or other disorders can become unable to move or speak despite being awake and alert. In this project, the investigators seek to further translate knowledge about interpreting brain signals related to movement, and to further develop an intracortical brain-computer interface (iBCI) that could restore rapid and intuitive use of communication apps on tablet computers by people with paraly... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
11/27/2024
Locations: Masssachusetts General Hospital, Boston, Massachusetts
Conditions: Brainstem Stroke, ALS, Tetraplegia, Spinal Cord Injuries, Cervical Spinal Cord Injury
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
Recruiting
The purpose of this research study is to test the safety and efficacy of cytokine induced memory-like (CIML) natural killer (NK) cells expanded with Interleukin-2 (IL-2) at preventing relapse in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or MDS and myeloproliferative neoplasm (MPN) overlap syndrome after a standard-of-care stem cell transplant. Names of the study therapies involved in this study are: * CIML NK cells intravenous infusion (cellular therapy) * Subcutaneous Inte... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/27/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Acute Myeloid Leukemia, Leukemia, Leukemia, Myeloid, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Myeloproliferative Disorders
AMT-260 Gene Therapy Study in Adults with Unilateral Refractory Mesial Temporal Lobe Epilepsy
Recruiting
This is a study of AMT-260 in Adults with Unilateral Refractory Mesial Temporal Lobe Epilepsy (MTLE). It is designed to investigate the Safety, Tolerability, and Efficacy of AMT-260 in Adults with MTLE Administered via Magnetic Resonance Imaging (MRI)-guided Convection-enhanced Delivery (CED).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
11/27/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Mesial Temporal Lobe Epilepsy
Medically Intensive Nutrition Therapy Program for Obesity and Diabetes in a Low-income Population
Recruiting
This study is being done to better understand whether meal replacements can be an effective tool for weight loss and treatment of elevated blood sugars in people with obesity/overweight and diabetes/pre-diabetes who have a low income.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
11/27/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Overweight, PreDiabetes, Diabetes Type 2, Obesity
Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia
Recruiting
The purpose of this study is to obtain preliminary device safety information and demonstrate proof of principle (feasibility) of the ability of people with tetraplegia to control a computer cursor and other assistive devices with their thoughts.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
11/27/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Anarthria, Dysarthria, Tetraplegia, Spinal Cord Injuries, Amyotrophic Lateral Sclerosis, Brain Stem Infarctions, Locked in Syndrome, Muscular Dystrophies
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Recruiting
The purpose of this study is to evaluate the efficacy and safety of tebentafusp-based regimens, including tebentafusp monotherapy and in combination with anti-PD1 vs investigator choice (including clinical trials of investigational agents, salvage therapy per local standard of care \[SoC\], best supportive care \[BSC\] on protocol survivor follow up) in patients with advanced non-ocular melanoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/27/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Advanced Melanoma
Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD
Recruiting
The objective of this study is to determine the safety and effectiveness of the smaller incision, new generation (SING), implantable miniature telescope (IMT) in patients with moderate-severe central vision loss due to late-stage age-related macular degeneration (AMD).
Gender:
ALL
Ages:
65 years and above
Trial Updated:
11/27/2024
Locations: Tallman Eye Associates, Lawrence, Massachusetts
Conditions: Age-Related Macular Degeneration, Geographic Atrophy
A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment
Recruiting
A study to evaluate the long-term risk of hepatic failure with TURALIO™ (pexidartinib) and the mechanism of liver injury based upon liver biopsy information among patients who received or are receiving TURALIO™ (pexidartinib) and experience hepatotoxicity.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/27/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Hepatotoxicity, Tenosynovial Giant Cell Tumor